ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFα release

International Immunopharmacology

Volumn 10, Issue 7, 2010, Pages 730-737

  Hua, Fei ^a   Henstock, Peter V ^a   Tang, Betty ^a  

^a PFIZER INC   (United States)

Author keywords

GM CSF; LPS; MEK inhibitor; p38 inhibitor; TNF

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 1ALPHA; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT INTERLEUKIN 6; SD 0006; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL STIMULATION; CELL STRAIN U937; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG POTENCY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MONOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ARTHRITIS, RHEUMATOID; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACROPHAGE ACTIVATION; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; U937 CELLS;

EID: 77953025999     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.04.002     Document Type: Article

References (33)

1. Ackermann C., and Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin Ther Targets 11 (2007) 1369-1384
2. Feldmann M., Brennan F.M., Elliott M.J., Williams R.O., and Maini R.N. TNF alpha is an effective therapeutic target for rheumatoid arthritis. Ann N Y Acad Sci 766 (1995) 272-278
3. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 97 (2002) 2000-2004
4. Ghosh S. Anti-TNF therapy in Crohn's disease. Novartis Found Symp 263 (2004) 193-205 [discussion 205-18]
5. de Boer W.I., Yao H., and Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis 2 (2007) 205-228
6. Scott D.L., and Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 355 (2006) 704-712
7. Rutault K., Hazzalin C.A., and Mahadevan L.C. Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction. Evidence for selective destabilization of TNF-alpha transcripts. J Biol Chem 276 (2001) 6666-6674
8. Lee J.C., Laydon J.T., McDonnell P.C., Gallagher T.F., Kumar S., Green D., et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372 (1994) 739-746
9. Swantek J.L., Cobb M.H., and Geppert T.D. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK. Mol Cell Biol 17 (1997) 6274-6282
10. Kontoyiannis D., Pasparakis M., Pizarro T.T., Cominelli F., and Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10 (1999) 387-398
11. Dumitru C.D., Ceci J.D., Tsatsanis C., Kontoyiannis D., Stamatakis K., Lin J.H., et al. TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell 103 (2000) 1071-1083
12. Scherle P.A., Jones E.A., Favata M.F., Daulerio A.J., Covington M.B., Nurnberg S.A., et al. Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 161 (1998) 5681-5686
13. Foxwell B., Browne K., Bondeson J., Clarke C., de Martin R., Brennan F., et al. Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent. Proc Natl Acad Sci U S A 95 (1998) 8211-8215
14. Tsytsykova A.V., Falvo J.V., Schmidt-Supprian M., Courtois G., Thanos D., and Goldfeld A.E. Post-induction, stimulus-specific regulation of tumor necrosis factor mRNA expression. J Biol Chem 282 (2007) 11629-11638
15. Swantek J.L., Christerson L., and Cobb M.H. Lipopolysaccharide-induced tumor necrosis factor-alpha promoter activity is inhibitor of nuclear factor-kappaB kinase-dependent. J Biol Chem 274 (1999) 11667-11671
16. Raabe T., Bukrinsky M., and Currie R.A. Relative contribution of transcription and translation to the induction of tumor necrosis factor-alpha by lipopolysaccharide. J Biol Chem 273 (1998) 974-980
17. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
18. Dinarello C.A. Role of pro- and anti-inflammatory cytokines during inflammation: experimental and clinical findings. J Biol Regul Homeost Agents 11 (1997) 91-103
19. Hueber W., Tomooka B.H., Zhao X., Kidd B.A., Drijfhout J.W., Fries J.F., et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 66 (2007) 712-719
20. Kumar S., Boehm J., and Lee J.C. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2 (2003) 717-726
21. Goldstein D.M., and Gabriel T. Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 5 (2005) 1017-1029
22. Sundstrom C., and Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer 17 (1976) 565-577
23. Dunne A., and O'Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003 (2003) re3
24. McLeish K.R., Knall C., Ward R.A., Gerwins P., Coxon P.Y., Klein J.B., et al. Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-alpha and GM-CSF. J Leukoc Biol 64 (1998) 537-545
25. Murray P.J. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc Natl Acad Sci U S A 102 (2005) 8686-8691
26. Hodge D.R., Hurt E.M., and Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41 (2005) 2502-2512
27. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., and Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003) 1-20
28. Ramana C.V., Gil M.P., Schreiber R.D., and Stark G.R. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol 23 (2002) 96-101
29. Hoffmeyer A., Grosse-Wilde A., Flory E., Neufeld B., Kunz M., Rapp U.R., et al. Different mitogen-activated protein kinase signaling pathways cooperate to regulate tumor necrosis factor alpha gene expression in T lymphocytes. J Biol Chem 274 (1999) 4319-4327
30. Jiang Y., Liu A., Qin Q., and Yin Z. Synergetic effect of mitogen-activated protein kinase pathway on expression of tumor necrosis factor alpha gene in RAW 264.7 cells induced by lipopolysaccharide. Zhonghua Yi Xue Za Zhi 82 (2002) 1410-1414
31. Schett G., Tohidast-Akrad M., Smolen J.S., Schmid B.J., Steiner C.W., Bitzan P., et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 43 (2000) 2501-2512
32. Schett G., Tohidast-Akrad M., Steiner G., and Smolen J. The stressed synovium. Arthritis Res 3 (2001) 80-86
33. Foey A.D., Parry S.L., Williams L.M., Feldmann M., Foxwell B.M., and Brennan F.M. Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-alpha: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 160 (1998) 920-928